PE-22-28 — EU research guide.
PE-22-28 is a synthetic peptide analogue of spadin, a fragment of the NTSR3/sortilin propeptide. It acts as a selective TREK-1 potassium channel blocker and has shown rapid antidepressant effects in animal models.
What is PE-22-28?
PE-22-28 is an optimised analogue of spadin — a natural peptide released from the propeptide of sortilin (NTSR3) during proteolytic processing. Spadin and PE-22-28 block the TREK-1 two-pore domain potassium channel, which plays a key role in setting neuronal excitability and mood. TREK-1 blockade in the hippocampus produces rapid antidepressant-like effects in rodent models.
What does the research show?
Rodent studies demonstrate faster-onset antidepressant effects than SSRIs in forced swim and tail suspension tests, with effects visible within hours rather than weeks. Neurogenesis in the hippocampus was enhanced. TREK-1 is a validated antidepressant target. No human clinical trials as of mid-2026. PE-22-28 represents early-stage mechanistic research into rapid-acting antidepressants.
EU legal status
Purely a research compound. No clinical development beyond preclinical stage. Available from EU vendors for laboratory neuropharmacology research only.
Molecular information
Pharmacokinetics
PE-22-28 across EU suppliers
COA-verified EU vendors · Updated monthly